MCID: INS002
MIFTS: 53

in Situ Carcinoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
ICD9CM 34 230-234.99
MeSH 43 D002278
NCIt 49 C2917
SNOMED-CT 67 109355002 68956006
ICD10 32 D09.9
UMLS 71 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and breast carcinoma in situ. An important gene associated with in Situ Carcinoma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Pravastatin and Sufentanil have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and lymph node, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 74 Carcinoma in situ (CIS) is a group of abnormal cells. While they are a form of neoplasm, there is... more...

Related Diseases for in Situ Carcinoma

Diseases in the in Situ Carcinoma family:

Pre-Malignant Neoplasm Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 711)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 34.2 TP53 PGR ESR1 ERBB2
2 breast carcinoma in situ 32.9 TP53 PGR MIR342 MIR181A1 MIR143 KRT5
3 vulvar intraepithelial neoplasia 32.6 TP53 CDH1
4 vulva cancer 31.4 TP53 ERBB2 EGFR
5 intraductal papilloma 31.3 PGR KRT5 ESR1 ERBB2
6 gynecomastia 31.3 PGR ESR1 ERBB2
7 bladder urothelial carcinoma 31.2 TP53 KRT5 ERBB2 EGFR CDH1
8 tubular adenocarcinoma 31.1 PGR ESR1 ERBB2 EGFR CDH1
9 sebaceous adenocarcinoma 31.1 TP53 KRT5 ERBB2
10 mammographic density 31.0 PGR ESR1
11 cervical squamous cell carcinoma 31.0 TP53 MIR143 EGFR CDH1
12 intrahepatic cholangiocarcinoma 31.0 TP53 ERBB2 EGFR CDH1
13 cholangiocarcinoma 31.0 TP53 ERBB2 EGFR CDH1
14 basal cell carcinoma 31.0 TP53 MIR143 KRT5 EGFR CDH1
15 larynx cancer 30.9 TP53 MIR143 MIR139 EGFR
16 adenosquamous carcinoma 30.8 TP53 PGR KRT5 EGFR
17 endometrial squamous cell carcinoma 30.7 TP53 PGR
18 endometrial hyperplasia 30.7 TP53 PGR ESR1
19 mammary paget's disease 30.7 PGR ESR1 ERBB2 EGFR
20 ductal carcinoma in situ 30.7 TP53 PGR KRT5 ESR1 ERBB2 EGFR
21 spindle cell carcinoma 30.7 PGR KRT5 ESR1 CDH1
22 cystadenocarcinoma 30.7 TP53 PGR ERBB2 BRCA1
23 verrucous carcinoma 30.7 TP53 KRT5 EGFR
24 female breast cancer 30.7 TP53 PGR ESR1 ERBB2 EGFR BRCA2
25 cholecystitis 30.7 TP53 EGFR CDH1
26 apocrine adenocarcinoma 30.6 TP53 PGR KRT5 ESR1 ERBB2 EGFR
27 tetraploidy 30.6 BRCA2 BRCA1
28 inverted papilloma 30.6 TP53 KRT5 EGFR
29 papilloma 30.6 TP53 KRT5 ESR1 EGFR CDH1
30 bronchiolo-alveolar adenocarcinoma 30.5 MIR126 EGFR CDH1
31 mucinous adenocarcinoma 30.5 TP53 PGR ESR1 ERBB2 EGFR
32 bilateral breast cancer 30.5 PGR ESR1 ERBB2 CDH1 BRCA2 BRCA1
33 lobular neoplasia 30.5 TP53 PGR KRT5 ESR1 ERBB2 CT45A10
34 carcinosarcoma 30.5 TP53 PGR ERBB2 EGFR CDH1
35 vaginal cancer 30.5 TP53 PRDX2 PGR ESR1
36 breast fibroadenoma 30.5 TP53 PGR ESR1 ERBB2 CT45A10 BRCA1
37 bladder disease 30.5 TP53 MIR181A1 MIR143 MIR139 MIR126
38 pleomorphic carcinoma 30.4 TP53 PGR EGFR
39 peutz-jeghers syndrome 30.4 TP53 EGFR BRCA2
40 papillary carcinoma 30.4 PGR ESR1 ERBB2 CDH1
41 cribriform carcinoma 30.4 PGR KRT5 ESR1 ERBB2
42 breast squamous cell carcinoma 30.4 KRT5 ERBB2
43 microglandular adenosis 30.4 TP53 PGR ESR1 ERBB2 EGFR CDH1
44 signet ring cell adenocarcinoma 30.4 TP53 ERBB2 CDH1
45 diffuse large b-cell lymphoma 30.4 TP53 MIR181A1 MIR143 MIR139 MIR126
46 vulvar disease 30.4 TP53 PGR ERBB2 EGFR
47 renal cell carcinoma, nonpapillary 30.4 TP53 MIR143 MIR139 MIR126 EGFR CDH1
48 papillary serous adenocarcinoma 30.4 TP53 PGR BRCA2 BRCA1
49 oral squamous cell carcinoma 30.3 TP53 MIR342 MIR181A1 MIR143 MIR139 MIR126
50 ovarian serous carcinoma 30.3 TP53 MIR143 ERBB2 CDH1

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.27 AGTR1 BRCA1 BRCA2 CDH1 EGFR ERBB2
3 digestive/alimentary MP:0005381 10.26 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
4 growth/size/body region MP:0005378 10.26 AGTR1 BRCA1 BRCA2 CDH1 EGFR ERBB2
5 cardiovascular system MP:0005385 10.25 AGTR1 BRCA1 CDH1 EGFR ERBB2 ESR1
6 endocrine/exocrine gland MP:0005379 10.19 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
7 integument MP:0010771 10.18 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
8 immune system MP:0005387 10.17 AGTR1 BRCA1 BRCA2 CDH1 EGFR ESR1
9 embryo MP:0005380 10.16 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
10 mortality/aging MP:0010768 10.13 AGTR1 BRCA1 BRCA2 CDH1 EGFR ERBB2
11 limbs/digits/tail MP:0005371 9.97 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
12 neoplasm MP:0002006 9.86 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
13 normal MP:0002873 9.81 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
14 renal/urinary system MP:0005367 9.56 AGTR1 BRCA1 EGFR ESR1 FKBP4 ITGB4
15 reproductive system MP:0005389 9.32 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1

Drugs & Therapeutics for in Situ Carcinoma

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
3
Ondansetron Approved Phase 4 99614-02-5 4595
4
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
5
BCG vaccine Investigational Phase 4
6 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
7 Lipid Regulating Agents Phase 4
8 Hypolipidemic Agents Phase 4
9 Anticholesteremic Agents Phase 4
10 Narcotics Phase 4
11 Anesthetics, General Phase 4
12 Analgesics, Opioid Phase 4
13 Anesthetics, Intravenous Phase 4
14 Vaccines Phase 4
15 Immunologic Factors Phase 4
16 Alkylating Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Mitomycins Phase 4
20 Adjuvants, Immunologic Phase 4
21
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
22
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
23
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
24
Bevacizumab Approved, Investigational Phase 3 216974-75-3
25
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
26
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
27
Aluminum sulfate Approved Phase 3 10043-01-3
28
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
29
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
30
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
31
Pembrolizumab Approved Phase 3 1374853-91-4
32
Fluorouracil Approved Phase 3 51-21-8 3385
33
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
34
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
35
leucovorin Approved Phase 3 58-05-9 6006 143
36
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
37
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
38
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
39
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
40
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
41
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
42
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
43
Daunorubicin Approved Phase 3 20830-81-3 30323
44
Cidofovir Approved Phase 3 113852-37-2 60613
45
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
46
Valrubicin Approved Phase 3 56124-62-0 41744
47
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
48
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
49
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
50
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469

Interventional clinical trials:

(show top 50) (show all 607)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
4 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
5 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
6 Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
7 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
8 The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. Recruiting NCT04248179 Phase 4 Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
9 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Not yet recruiting NCT03221062 Phase 4
10 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
11 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
12 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
13 Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks. Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
14 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
15 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
16 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
17 SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS Unknown status NCT00629278 Phase 3 aromatase inhibition therapy;cyclophosphamide;docetaxel;doxorubicin hydrochloride;epirubicin hydrochloride;fluorouracil;paclitaxel;releasing hormone agonist therapy;tamoxifen citrate
18 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
19 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
20 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
21 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
22 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
23 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
24 An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
25 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
26 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
27 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
28 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
29 A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
30 A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ Completed NCT00003779 Phase 3
31 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
32 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
33 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) Completed NCT00106691 Phase 3 Toremifene 20 mg;Placebo
34 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
35 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
36 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
37 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
38 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
39 A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer Completed NCT00233402 Phase 3 Hexvix
40 Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group) Completed NCT02295033 Phase 3
41 A Prospective, Randomized, Open-label, Multicentric,phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients Completed NCT01216111 Phase 3 Paclitaxel Cisplatin;fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
42 A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
43 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
44 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
45 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
46 Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy Completed NCT00352404 Phase 3
47 A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen Completed NCT00003140 Phase 3 letrozole
48 Photodynamic Diagnosis (PDD) in Flexible Cystoscopy - DaBlaCa-11 Completed NCT02660190 Phase 3 hexaminoavolunate
49 A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC) Completed NCT03288987 Phase 3 Bevacizumab + FOLFIRI-3
50 A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma Completed NCT00312000 Phase 3 capecitabine-irinotecan;capecitabine+irinotecan (1st line)

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

40
Breast, Cervix, Lymph Node, Lung, Testis, Testes, Skin

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 17387)
# Title Authors PMID Year
1
Corneal melt in conjunctival intraepithelial neoplasia. 61
32426552 2020
2
Early intervention exercise training does not delay prostate cancer progression in Pten-/- mice. 61
32519789 2020
3
Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision. 61
32144463 2020
4
A rare case of nasal Schneiderian (inverted) papilloma associated with basaloid squamous cell carcinoma. 61
32534706 2020
5
Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. 61
32302762 2020
6
Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good? 61
32430678 2020
7
Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition. 61
32134153 2020
8
The 2018 assisi think tank meeting on breast cancer: International expert panel white paper. 61
32450277 2020
9
The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. 61
31933123 2020
10
Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling. 61
31907974 2020
11
Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. 61
32427633 2020
12
Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS. 61
32454975 2020
13
Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer. 61
32447596 2020
14
Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. 61
31974710 2020
15
CRISP3 expression drives prostate cancer invasion and progression. 61
32357309 2020
16
Sebaceous Carcinoma In Situ of the External Auditory Canal. 61
32569248 2020
17
The impact of ductal carcinoma in situ on health services utilization. 61
32385793 2020
18
Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes. 61
30910393 2020
19
Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study. 61
32506248 2020
20
Screening Mammography Outcomes: Risk of Breast Cancer and Mortality by Comorbidity Score and Age. 61
31593591 2020
21
Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer. 61
32084524 2020
22
Stromal Collagen Content in Breast Tumors Correlates With In Vivo Diffusion-Weighted Imaging: A Comparison of Multi b-Value DWI With Histologic Specimen From Benign and Malignant Breast Lesions. 61
31837076 2020
23
Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. 61
32478867 2020
24
[Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation vs. whole breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and node-negative breast cancer : The multicentric randomised RAPID trial]. 61
32342118 2020
25
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer. 61
32103597 2020
26
The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort. 61
32311194 2020
27
Omics Integration Analyses Reveal the Early Evolution of Malignancy in Breast Cancer. 61
32512721 2020
28
Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience. 61
31218842 2020
29
A mouse SWATH-MS reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts. 61
32493768 2020
30
Stem Cell Determinant SOX9 Promotes Lineage Plasticity and Progression in Basal-like Breast Cancer. 61
32521267 2020
31
Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis. 61
32522804 2020
32
Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. 61
32569566 2020
33
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. 61
32201133 2020
34
TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. 61
32533903 2020
35
Long-Term Outcomes of Multiple-Wire Localizations for More Extensive Breast Cancer: Multiple-Wire Excision Does Not Increase Recurrence, Unplanned Imaging, or Biopsies. 61
31859233 2020
36
Potential Role of Convolutional Neural Network Based Algorithm in Patient Selection for DCIS Observation Trials Using a Mammogram Dataset. 61
31526687 2020
37
Adjuvant endocrine treatment for estrogen receptor (ER)-positive/ HER2-negative breast cancer. 61
32527118 2020
38
Successful treatment for multiple Bowen's disease using photodynamic therapy: A case report. 61
32330610 2020
39
The 1960s cervical screening incident at National Women's Hospital, Auckland, New Zealand: insights for screening research, policy making, and practice. 61
32448444 2020
40
Membranous overexpression of S100A10 is associated with a high-grade cellular status of breast carcinoma. 61
31728728 2020
41
Histopathologic Analysis of Signet-ring Cell Carcinoma In Situ in Patients With Hereditary Diffuse Gastric Cancer. 61
32520759 2020
42
Photodynamic therapy in combination with surgery for the treatment of an extensive squamous cell carcinoma in situ - A case report. 61
32126306 2020
43
Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy. 61
31471739 2020
44
Carcinogenesis of Pancreatic Ductal Adenocarcinoma. 61
32199881 2020
45
The predictive value of positive and suspicious urine cytology: Are they different? 61
32558388 2020
46
Pathfinders in oncology from the beginning of modern surgery of intracranial tumors to the introduction of the Pap smear. 61
32196649 2020
47
Non-invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas. 61
32500575 2020
48
Inter-observer reproducibility of classical lobular neoplasia (B3 lesions) in preoperative breast biopsies: a study of the Swiss Working Group of breast and gynecopathologists. 61
32232656 2020
49
Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. 61
31907376 2020
50
ASO Author Reflections: Conceptualizing Risk in Women with Lobular Carcinoma In Situ. 61
32246310 2020

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 12.64 TP53 ESR1 ERBB2 EGFR CDH1 BRCA2
2
Show member pathways
12.46 TP53 ESR1 ERBB2 EGFR CDH1 BRCA2
3
Show member pathways
12.22 TP53 PGR ESR1 ERBB2 EGFR CDH1
4 12.12 TP53 ESR1 ERBB2 EGFR
5
Show member pathways
12.02 PGR NR3C1 ESR1 BRCA1
6 11.82 TP53 ESR1 EGFR CDH1 BRCA2 BRCA1
7
Show member pathways
11.79 PGR ESR1 ERBB2 EGFR
8
Show member pathways
11.74 ESR1 ERBB2 EGFR
9 11.73 FKBP4 EGFR BRCA1
10 11.72 TP53 MIR342 MIR181A1 MIR143 MIR126 ERBB2
11
Show member pathways
11.71 PGR NR3C1 ESR1
12
Show member pathways
11.67 TP53 BRCA2 BRCA1
13 11.65 TP53 NR3C1 KRT5 FKBP4
14 11.6 TP53 ERBB2 BRCA1
15 11.57 ERBB2 EGFR CDH1
16 11.57 TP53 ERBB2 EGFR CDH1
17 11.56 TP53 ERBB2 EGFR
18 11.52 TP53 ERBB2 BRCA1
19 11.46 ITGB4 ERBB2 BRCA1
20 11.05 ITGB4 ERBB2 EGFR CDH1
21 10.57 NR3C1 FKBP4

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.17 TP53 NR3C1 FKBP4 ESR1 EGFR BRCA2

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.86 TP53 PRDX2 ESR1 BRCA1
2 regulation of cell proliferation GO:0042127 9.78 TP53 EGFR BRCA1 AGTR1
3 positive regulation of inflammatory response GO:0050729 9.74 MIR126 EGFR AGTR1
4 double-strand break repair GO:0006302 9.63 TP53 BRCA2 BRCA1
5 positive regulation of transcription, DNA-templated GO:0045893 9.63 TP53 ESR1 EGFR CDH1 BRCA2 BRCA1
6 hemidesmosome assembly GO:0031581 9.55 KRT5 ITGB4
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 EGFR
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.54 MIR342 MIR143 MIR126
9 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.52 TP53 ESR1
10 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.51 TP53 ESR1
11 angiotensin-activated signaling pathway GO:0038166 9.49 MIR143 AGTR1
12 negative regulation of ERBB signaling pathway GO:1901185 9.43 ERBB2 EGFR
13 hydrogen peroxide metabolic process GO:0042743 9.4 PRDX2 EGFR
14 positive regulation of protein kinase B signaling GO:0051897 9.35 MIR143 MIR126 ESR1 ERBB2 EGFR
15 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 BRCA1
16 chordate embryonic development GO:0043009 9.26 BRCA2 BRCA1
17 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 TP53 BRCA2 BRCA1

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.65 TP53 PGR ESR1 EGFR BRCA1
2 protein phosphatase binding GO:0019903 9.63 TP53 ERBB2 EGFR
3 ATPase binding GO:0051117 9.61 PGR ESR1 EGFR
4 identical protein binding GO:0042802 9.56 TP53 PGR ESR1 ERBB2 EGFR CDH1
5 steroid hormone receptor activity GO:0003707 9.54 PGR NR3C1 ESR1
6 repressing transcription factor binding GO:0070491 9.5 PGR NR3C1 ESR1
7 nitric-oxide synthase regulator activity GO:0030235 9.4 ESR1 EGFR
8 nuclear receptor activity GO:0004879 9.33 PGR NR3C1 ESR1
9 steroid binding GO:0005496 8.8 PGR NR3C1 ESR1

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....